SHELTON, CT - January 21, 2014 (Investorideas.com Newswire) NXT-ID (OTCQB: NXTD), a biometrics company focused on the growing m-commerce market, announces it will be doing a joint project with students at the John F. Welch College of Business at Sacred Heart University in Fairfield, CT to assist with the marketing roll out of its next generation smart wallet, the Wocket™.

The Wocket™ is a new biometrically secure smart wallet designed to replace the traditional wallet and the number of cards consumers carry. Its dynamically programmable magnetic stripe, NXTCard can replace more than 100 cards and can include medical records, ID, coupons etc. that are currently kept in a wallet, with one single secure card.

Read more: Biometric Stock Alert: Mobile Biometric Company NXT-ID, Inc. (OTCQB: NXTD) to Team With the John...

 MONTREAL, QC - January 21, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is now targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.

Read more: Biotech News Alert: Sunshine Biopharma (OTCQB: SBFM) Targets Pancreatic Cancer as Second...

 New York NY - Point Roberts WA - January 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues an exclusive interview with Dr. Madi R. Madiyalakan, Ph.D., Chief Executive Officer of Quest PharmaTech Inc. (TSX.V: QPT). Dr. Madiyalakan shares insight into the Company’s pipeline of oncology products. The Company takes a unique approach to cancer treatment that capitalizes on the recent major advances in the understanding of immune physiology and developing proprietary next generation cancer immunotherapy treatments using select antibodies, adjuvants and photosensitizers.

Interview:

Q: Investorideas.com

For readers unfamiliar with your company, can you give a brief introduction on your background in the biotech space and the formation of Quest PharmaTech?

Read more: TSX Biotech Stock: Q&A Interview with CEO of Quest PharmaTech (TSX.V: QPT)

An Overview of the Phosphate Market

Late last year, I highlighted phosphate as one of the critical natural resources we will focus on in 2014

The phosphate story is the story of security of supply because much of global phosphate supply originates from geopolitically unstable regions of the world

The key to success is secure access to low cost phosphate rock. Supply of this resource

www.discoveryinvesting.com

 - [ Discovery Investing Web Site ]

alt

 New York, NY, Point Roberts, WA - December 19, 2013 (Investorideas.com Biotech Newswire) Investorideas.com, a research and news portal covering leading sectors, issues an exclusive Q&A interview with Dr. Steve N. Slilaty Ph.D., Chairman and CEO of Sunshine Biopharma Inc. (OTCQB: SBFM). Sunshine is Biopharma a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

Dr. Steve N. Slilaty shares insight to the recent news that it has re-domiciled in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations, in addition to updating the current status of its lead cancer product Adva-27a.

Read more: Biopharma Q&A Interview; Dr. Steve N. Slilaty Ph.D., Chairman, CEO of Sunshine Biopharma (OTCQB:...